US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

SpyGlass Pharma, Inc.

22.61

-2.5900-10.28%

Post-market: 22.610.00000.00%16:19 EDT

Volume:95.38K

Turnover:2.14M

Market Cap:753.31M

PE:-21.09

High:24.63

Open:24.63

Low:21.29

Close:25.20

52wk High:32.44

52wk Low:20.16

Shares:33.32M

Float Shares:10.78M

Volume Ratio:0.40

T/O Rate:0.88%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.0720

ROE:-67.71%

ROA:-37.23%

PB:-7.62

PE(LYR):- -

Loading ...

Overview Company News Filings

Analysts Offer Insights on NA Companies: BitGo Holdings, Inc. Class A (BTGO) and SpyGlass Pharma (Nasdaq: SGP)

SpyGlass Pharma Q4 EPS $(5.72) Down From $(4.58) YoY

Spyglass Pharma Inc: Q4 Net Loss $5.72 per Basic and Diluted Share

THOMSON REUTERS

SpyGlass Pharma FY2025 net loss widened 36.64% to $39.9 million; loss per share widened to $17.98

Press Release: SpyGlass Pharma Reports Fourth Quarter and Full Year 2025 Earnings and Provides a Corporate Update

SpyGlass Pharma: Differentiated BIM-IOL Platform and Favorable Risk-Reward Support Buy Rating Ahead of 2028 NDA Catalyst

Jefferies Remains a Buy on SpyGlass Pharma (SGP)

SpyGlass Pharma Initiated at Buy by HC Wainwright & Co.

De‑Risking Milestone and Pipeline Catalysts Underpin High‑Risk Buy on SpyGlass Pharma

SpyGlass Pharma initiated with a Buy at H.C. Wainwright

Spyglass Pharma, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating

THOMSON REUTERS

Spyglass Pharma Announces Positive Topline 12-Month Phase 1/2 Trial Results for Its Innovative Bim-Iol System

THOMSON REUTERS

SpyGlass Pharma Announces Positive Topline 12-Month Phase 1/2 Trial Results for Its Innovative BIM-IOL System

SpyGlass Pharma to Host 1x1 Meetings at Jefferies Biotech on the Bay Summit in Miami Beach

SpyGlass Pharma Initiated at Buy by Jefferies

SpyGlass Pharma: De-risked BIM-IOL Platform Poised to Reshape Glaucoma Treatment and Drive Upside to Conservative Peak Sales Estimates

Leerink Initiates at Outperform With $42 Price Target

MT Newswires Live

Jefferies Initiates SpyGlass Pharma at Buy With $62 Price Target

MT Newswires Live

SpyGlass Pharma initiated with a Buy at Citi

Stockland’s Earnings Lift And Steady Payout Guidance Could Be A Game Changer For Stockland (ASX:SGP)

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/SGP/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SGP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SGP\",,,,,undefined,":{"symbol":"SGP","market":"US","secType":"STK","nameCN":"SpyGlass Pharma, Inc.","latestPrice":22.61,"timestamp":1774641600000,"preClose":25.2,"halted":0,"volume":95381,"hourTrading":{"tag":"盘后","latestPrice":22.61,"preClose":22.61,"latestTime":"16:19 EDT","volume":72,"amount":1651.27,"timestamp":1774642782776,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.10277777777777777,"floatShares":10781300,"shares":33317414,"eps":-1.072,"marketStatus":"Market Closed","change":-2.59,"latestTime":"03-27 16:00:00 EDT","open":24.63,"high":24.63,"low":21.29,"amount":2143710.0721,"amplitude":0.13254,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-1.072,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":7,"adr":0,"listingDate":1770354000000,"exchange":"NASDAQ","adjPreClose":25.2,"preHourTrading":{"tag":"盘前","latestPrice":25.49,"preClose":25.2,"latestTime":"08:01 EDT","volume":1,"amount":25.49,"timestamp":1774612862032,"change":0.29,"changeRate":0.011508,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":22.61,"preClose":22.61,"latestTime":"16:19 EDT","volume":72,"amount":1651.27,"timestamp":1774642782776,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.399183561727348},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SGP\",,,,,undefined,":{"symbol":"SGP","floatShares":10781300,"roa":"-37.23%","roe":"-67.71%","lyrEps":0,"volumeRatio":0.399183561727348,"shares":33317414,"dividePrice":0,"high":24.63,"amplitude":0.13254,"preClose":25.2,"low":21.29,"week52Low":20.16,"pbRate":"-7.62","week52High":32.44,"institutionHeld":0,"latestPrice":22.61,"eps":-1.072,"divideRate":0,"volume":95381,"delay":0,"ttmEps":-1.072,"open":24.63,"prevYearClose":16,"prevWeekClose":26,"prevMonthClose":28,"prevQuarterClose":16,"fiveDayClose":26,"twentyDayClose":28,"sixtyDayClose":16},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SGP\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SGP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SGP\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.75,"buy":0.25,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.75,"analysts":4,"updateTime":1773201600000},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SGP\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2622564822","title":"Analysts Offer Insights on NA Companies: BitGo Holdings, Inc. Class A (BTGO) and SpyGlass Pharma (Nasdaq: SGP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2622564822","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622564822?lang=en_us&edition=fundamental","pubTime":"2026-03-27 21:10","pubTimestamp":1774617046,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the NA sector as 2 analysts just weighed in on BitGo Holdings, Inc. Class A (BTGO) and SpyGlass Pharma (SGP...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-bitgo-holdings-inc-class-a-btgo-and-spyglass-pharma-nasdaq-sgp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-bitgo-holdings-inc-class-a-btgo-and-spyglass-pharma-nasdaq-sgp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BTGO","NA","SGP","BK4127","BK4141","NQmain"],"gpt_icon":0},{"id":"2622896078","title":"SpyGlass Pharma Q4 EPS $(5.72) Down From $(4.58) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2622896078","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622896078?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:21","pubTimestamp":1774556467,"startTime":"0","endTime":"0","summary":"SpyGlass Pharma (NASDAQ:SGP) reported quarterly losses of $(5.72) per share. This is a 24.89 percent decrease over losses of $(4.58) per share from the same period last year.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51495858/spyglass-pharma-q4-eps-5-72-down-from-4-58-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"SpyGlass Pharma Q4 EPS $(5.72) Down From $(4.58) YoY","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGP"],"gpt_icon":0},{"id":"2622964308","title":"Spyglass Pharma Inc: Q4 Net Loss $5.72 per Basic and Diluted Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2622964308","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622964308?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:09","pubTimestamp":1774555762,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nFWN40E128:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","SGP"],"gpt_icon":0},{"id":"2622896499","title":"SpyGlass Pharma FY2025 net loss widened 36.64% to $39.9 million; loss per share widened to $17.98","url":"https://stock-news.laohu8.com/highlight/detail?id=2622896499","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622896499?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:09","pubTimestamp":1774555760,"startTime":"0","endTime":"0","summary":"SpyGlass Pharma filed a Form 8-K reporting fourth-quarter and full-year 2025 results and a corporate update, including the completion of its IPO raising USD 172.5 million in gross proceeds and a Nasdaq listing.Cash, cash equivalents and short-term investments were USD 107.4 million at year-end 2025, and the company said its cash position including IPO proceeds is expected to fund planned operations through 2028.R&D expense rose 35.09% to USD 7.7 million in Q4 and increased 46% to USD 29.2 million for FY 2025, driven by hiring clinical and research personnel and initiating registrational Phase 3 trials for the BIM-IOL System.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyglass Pharma Inc. published the original content used to gener","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL8gZ4Dk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","SGP"],"gpt_icon":0},{"id":"2622896144","title":"Press Release: SpyGlass Pharma Reports Fourth Quarter and Full Year 2025 Earnings and Provides a Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2622896144","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622896144?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:05","pubTimestamp":1774555500,"startTime":"0","endTime":"0","summary":"-- Successfully completed Initial Public Offering  in February 2026,-- Phase 3 trials of BIM-IOL System are ongoing, with enrollment underway. 12-Month Phase 1/2 Data of BIM-IOL System. In March 2026, SpyGlass Pharma announced positive topline results from its Phase 1/2 trial of the BIM-IOL System, which evaluated two dose levels of 78-mcg , the intended commercial dose, and 39-mcg  compared to a physician's choice of commercially available monofocal IOLs from Alcon, Bausch + Lomb or Johnson & Johnson with twice-daily administration of timolol eyedrops as the control group . Evaluable patients receiving the BIM-IOL System achieved a time-matched reduction of 34% and 42% in mean IOP from baseline in the high and low dose groups respectively, compared to a 35% reduction in the control group at 8 a.m. Results were similar at the 10 a.m. timepoint. Additionally, 98% of evaluable patients  in the 78-mcg dose group and 96% of evaluable patients  in the 39-mcg dose group were free from all to","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGP"],"gpt_icon":0},{"id":"2618957548","title":"SpyGlass Pharma: Differentiated BIM-IOL Platform and Favorable Risk-Reward Support Buy Rating Ahead of 2028 NDA Catalyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2618957548","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618957548?lang=en_us&edition=fundamental","pubTime":"2026-03-11 00:35","pubTimestamp":1773160541,"startTime":"0","endTime":"0","summary":"Yi Chen, an analyst from H.C. Wainwright, has initiated a new Buy rating on SpyGlass Pharma (SGP). Yi Chen has given his Buy rating due to a combin...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/spyglass-pharma-differentiated-bim-iol-platform-and-favorable-risk-reward-support-buy-rating-ahead-of-2028-nda-catalyst-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/spyglass-pharma-differentiated-bim-iol-platform-and-favorable-risk-reward-support-buy-rating-ahead-of-2028-nda-catalyst-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SGP"],"gpt_icon":0},{"id":"2618999953","title":"Jefferies Remains a Buy on SpyGlass Pharma (SGP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2618999953","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618999953?lang=en_us&edition=fundamental","pubTime":"2026-03-10 20:55","pubTimestamp":1773147340,"startTime":"0","endTime":"0","summary":"Jefferies analyst Dennis Ding reiterated a Buy rating on SpyGlass Pharma today and set a price target of $62.00. Ding covers the Healthcare sector,...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jefferies-remains-a-buy-on-spyglass-pharma-sgp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jefferies-remains-a-buy-on-spyglass-pharma-sgp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","XLV","BK4007","LABU","SGP","BK4581","XBI","BK4585"],"gpt_icon":0},{"id":"2618932921","title":"SpyGlass Pharma Initiated at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2618932921","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618932921?lang=en_us&edition=fundamental","pubTime":"2026-03-10 19:25","pubTimestamp":1773141900,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SGP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 10, 2026 07:25 ET (11:25 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGP","BK4007"],"gpt_icon":0},{"id":"2618393499","title":"De‑Risking Milestone and Pipeline Catalysts Underpin High‑Risk Buy on SpyGlass Pharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2618393499","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618393499?lang=en_us&edition=fundamental","pubTime":"2026-03-10 18:56","pubTimestamp":1773140169,"startTime":"0","endTime":"0","summary":"Citi analyst Yigal Nochomovitz has maintained their bullish stance on SGP stock, giving a Buy rating today. Yigal Nochomovitz has given his Buy rat...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/de‑risking-milestone-and-pipeline-catalysts-underpin-high‑risk-buy-on-spyglass-pharma-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/de‑risking-milestone-and-pipeline-catalysts-underpin-high‑risk-buy-on-spyglass-pharma-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","SGP"],"gpt_icon":0},{"id":"2618939904","title":"SpyGlass Pharma initiated with a Buy at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2618939904","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618939904?lang=en_us&edition=fundamental","pubTime":"2026-03-10 18:21","pubTimestamp":1773138075,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Yi Chen initiated coverage of SpyGlass Pharma (SGP) with a Buy rating and $37 price target SpyGlass is a clinical-stage bio...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/spyglass-pharma-initiated-with-a-buy-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/spyglass-pharma-initiated-with-a-buy-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SGP","BK4007"],"gpt_icon":0},{"id":"2618393099","title":"Spyglass Pharma, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2618393099","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618393099?lang=en_us&edition=fundamental","pubTime":"2026-03-10 18:16","pubTimestamp":1773137783,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nAZN4SKHSL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","SGP"],"gpt_icon":0},{"id":"2618762588","title":"Spyglass Pharma Announces Positive Topline 12-Month Phase 1/2 Trial Results for Its Innovative Bim-Iol System","url":"https://stock-news.laohu8.com/highlight/detail?id=2618762588","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618762588?lang=en_us&edition=fundamental","pubTime":"2026-03-09 20:00","pubTimestamp":1773057600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nTUA8K96XW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SGP","BK4007"],"gpt_icon":0},{"id":"2618434625","title":"SpyGlass Pharma Announces Positive Topline 12-Month Phase 1/2 Trial Results for Its Innovative BIM-IOL System","url":"https://stock-news.laohu8.com/highlight/detail?id=2618434625","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618434625?lang=en_us&edition=fundamental","pubTime":"2026-03-09 20:00","pubTimestamp":1773057600,"startTime":"0","endTime":"0","summary":"97% of patients who received the BIM-IOL System off all topical IOP-lowering therapy at 12-months100% of BIM-IOL System patients achieved 20/32 or better BCDVA and a mean BCDVA equivalent to 20/20 vis","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/09/3251760/0/en/SpyGlass-Pharma-Announces-Positive-Topline-12-Month-Phase-1-2-Trial-Results-for-Its-Innovative-BIM-IOL-System.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGP","BK4007"],"gpt_icon":0},{"id":"2616558928","title":"SpyGlass Pharma to Host 1x1 Meetings at Jefferies Biotech on the Bay Summit in Miami Beach","url":"https://stock-news.laohu8.com/highlight/detail?id=2616558928","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616558928?lang=en_us&edition=fundamental","pubTime":"2026-03-04 21:02","pubTimestamp":1772629358,"startTime":"0","endTime":"0","summary":"SpyGlass Pharma to Host 1x1 Meetings at Jefferies Biotech on the Bay Summit in Miami Beach               SpyGlass Pharma Inc. will host one-on-one meetings at the Jefferies Biotech on the Bay Summit i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nNDL42Kg64:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","SG9999014005.SGD","SG9999014021.USD","LU2095319765.USD","LU0314104364.USD","LU2210149790.SGD","SGP","IE00BKPKM429.USD","BK4112","BK4007","NDAQ","SG9999014013.SGD","LU2210150020.SGD","SG9999014039.USD","BK4588","BK4585"],"gpt_icon":0},{"id":"2616632835","title":"SpyGlass Pharma Initiated at Buy by Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2616632835","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616632835?lang=en_us&edition=fundamental","pubTime":"2026-03-03 21:05","pubTimestamp":1772543100,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SGP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 03, 2026 08:05 ET (13:05 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","SGP"],"gpt_icon":0},{"id":"2616754347","title":"SpyGlass Pharma: De-risked BIM-IOL Platform Poised to Reshape Glaucoma Treatment and Drive Upside to Conservative Peak Sales Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2616754347","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616754347?lang=en_us&edition=fundamental","pubTime":"2026-03-03 20:35","pubTimestamp":1772541342,"startTime":"0","endTime":"0","summary":"Yigal Nochomovitz, an analyst from Citi, has initiated a new Buy rating on SpyGlass Pharma (SGP). Yigal Nochomovitz has given his Buy rating due to...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/spyglass-pharma-de-risked-bim-iol-platform-poised-to-reshape-glaucoma-treatment-and-drive-upside-to-conservative-peak-sales-estimates-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/spyglass-pharma-de-risked-bim-iol-platform-poised-to-reshape-glaucoma-treatment-and-drive-upside-to-conservative-peak-sales-estimates-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SKIS","SGP"],"gpt_icon":0},{"id":"2616772342","title":"Leerink Initiates at Outperform With $42 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2616772342","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616772342?lang=en_us&edition=fundamental","pubTime":"2026-03-03 20:18","pubTimestamp":1772540314,"startTime":"0","endTime":"0","summary":"Leerink Initiates at Outperform With $42 Price Target","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","SGP"],"gpt_icon":0},{"id":"2616342774","title":"Jefferies Initiates SpyGlass Pharma at Buy With $62 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2616342774","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616342774?lang=en_us&edition=fundamental","pubTime":"2026-03-03 20:17","pubTimestamp":1772540250,"startTime":"0","endTime":"0","summary":"Jefferies Initiates SpyGlass Pharma at Buy With $62 Price Target","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SGP"],"gpt_icon":0},{"id":"2616491513","title":"SpyGlass Pharma initiated with a Buy at Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=2616491513","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616491513?lang=en_us&edition=fundamental","pubTime":"2026-03-03 18:41","pubTimestamp":1772534482,"startTime":"0","endTime":"0","summary":"Citi initiated coverage of SpyGlass Pharma (SGP) with a Buy rating and $42 price target The firm sees a positive risk/reward despite the stock’s 70...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/spyglass-pharma-initiated-with-a-buy-at-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/spyglass-pharma-initiated-with-a-buy-at-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","SGP"],"gpt_icon":0},{"id":"2616840019","title":"Stockland’s Earnings Lift And Steady Payout Guidance Could Be A Game Changer For Stockland (ASX:SGP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2616840019","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616840019?lang=en_us&edition=fundamental","pubTime":"2026-03-01 09:26","pubTimestamp":1772328402,"startTime":"0","endTime":"0","summary":"In February 2026, Stockland reported half-year net income of A$292 million and higher earnings per share than a year earlier, alongside confirming an increased interim distribution of A$0.09 per security and guiding to a full-year 2026 payout in line with the prior year at 25.2 cents per security.\nThis combination of stronger profitability and clearer income guidance has sharpened investor focus on Stockland’s capacity to sustain cash returns while funding its development pipeline.\nNext,...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/9551731-choice2-main-header/1585186650529","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551731-choice2-main-header/1585186650529"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/real-estate/asx-sgp/stockland-shares/news/stocklands-earnings-lift-and-steady-payout-guidance-could-be","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/real-estate/asx-sgp/stockland-shares/news/stocklands-earnings-lift-and-steady-payout-guidance-could-be","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SGP"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":37,"code":"91000000","status":"200"}]}}